Mode
Text Size
Log in / Sign up
N/A Completed N=1,377

ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking

Source: ClinicalTrials.gov NCT00808015 ↗
Enrolled (actual)
1,377
Serious AEs
0.8%
Results posted
Jul 2011
Primary outcomePrimary: Percentage of Participants With Smoking Abstinence at Week 12 — 46.40 percentage of participants

Summary

The purpose of this study is to describe the characteristics of the smoker who wants to quit and his/her treating physician, in addition to determine the safety and effectiveness of Champix in the real-world setting of smokers in routine clinical practice.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With Smoking Abstinence at Week 12
46.40 —
SECONDARY
Percentage of Participants With Smoking Abstinence Before Last Observed Study Visit
50.30 —
SECONDARY
Percentage of Participants With Smoking Abstinence Status From Week 3 to Week 11
31.3; 38.2; 45.4; 47.8; 49.5; 51.6 —
SECONDARY
CO Level at Last Observed Study Visit
4.1 —
SECONDARY
Average Weekly Number of Cigarettes Smoked at Last Observed Study Visit
10.0 —

Eligibility Criteria

Inclusion Criteria

  • All patients enrolled should meet the usual prescribing criteria for Champix® as per the local product information and should be entered into the trial at the investigator's discretion

Exclusion Criteria

  • All patients enrolled should meet the usual prescribing criteria for Champix® as per the local product information and should be entered into the trial at the investigator's discretion
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00808015). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search